1 |
Turner N, Ware O, Bosenberg M. Genetics of metastasis: melanoma and other cancers[J]. Clin Exp Metastasis, 2018, 35(5/6): 379-391.
|
2 |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
|
3 |
Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma[J]. Lancet, 2018, 392(10151): 971-984.
|
4 |
CSCO黑色素瘤专家委员会. 中国黑色素瘤诊治指南[M]. 北京: 人民卫生出版社, 2015: 20-22.
|
|
CSCO Expert Committee on Melanoma. Guidelines for diagnosis and treatment of melanoma in China[M]. Beijing: People's Medical Publishing House, 2015: 20-22.
|
5 |
Siegel RL, Miller KD, Jemal A, et al. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30.
|
6 |
中国临床肿瘤学会. 恶性黑色素瘤诊疗指南2019版[M]. 北京: 人民卫生出版社, 2019: 54-60.
|
|
Chinese Society of Clinical Oncology. Guidelines for diagnosis and treatment of malignant melanoma, 2019[M]. Beijing: People's Medical Publishing House, 2019: 54-60.
|
7 |
Leung AM, Hari DM, Morton DL. Surgery for distant melanoma metastasis[J]. Cancer J, 2012, 18(2): 176-184.
|
8 |
Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in stageⅢbraf-mutated melanoma[J]. N Engl J Med, 2017, 377(19): 1813-1823.
|
9 |
Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified kit arising on mucosal, acral, and chronically sun-damaged skin[J]. J Clin Oncol, 2013, 31(26): 3182-3190.
|
10 |
中国抗癌协会肉瘤专业委员会软组织肉瘤及恶性黑色素瘤学组. 皮肤和肢端恶性黑色素瘤的外科治疗规范中国专家共识1.0[J]. 中华肿瘤杂志, 2020, 42(2): 81-93.
|
|
Soft Tissue Sarcoma And Malignant Melanoma Group, Sarcomas Committee, Chinese Society of Clinical Oncology. Chinese expert consensus on surgical treatment of cutaneous and acral malignant melanoma 1.0[J]. Chin J Oncol, 2020, 42(2): 81-93.
|
11 |
Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma[J]. N Engl J Med, 2004, 351: 998-1012.
|
12 |
Ugurel S, Röhmel J, Ascierto PA, et al. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017[J]. Eur J Cancer, 2017, 83: 247-257.
|
13 |
Lyu J, Wu Y, Li C, et al. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases[J]. J Oral Pathol Med, 2016, 45(4): 295-301.
|
14 |
Hwang SJE, Fernández-Peñas P. Adverse reactions to biologics: melanoma (ipilimumab, nivolumab, pembrolizumab)[J]. Curr Probl Dermatol, 2018, 53: 82-92.
|
15 |
Collins LK, Chapman MS, Carter JB, et al. Cutaneous adverse effects of the immune checkpoint inhibitors[J]. Curr Probl Cancer, 2017, 41(2): 125-128.
|
16 |
Seyed MA, Jantan I, Bukhari SN, et al. A comprehensive review on the chemotherapeutic potential of picea-tannol for cancer treatment, with mechanistic insights[J]. J Agric Food Chem, 2016, 64(4): 725-737.
|
17 |
Surh YJ, Na HK. Therapeutic potential and molecular targets of piceatannol in chronic diseases[J]. Adv Exp Med Biol, 2016, 928: 185-211.
|
18 |
Banik K, Ranaware AM, Harsha C, et al. Piceatannol: a natural stilbene for the prevention and treatment of cancer[J]. Pharmacol Res, 2020, 153: 104635.
|
19 |
Du M, Zhang Z, Gao T. Piceatannol induced apoptosis through up-regulation of microRNA-181a in melanoma cells[J]. Biol Res, 2017, 50(1): 36.
|
20 |
Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019[J]. CA Cancer J Clin, 2019, 69(5): 363-385.
|
21 |
Molina G, Kasumova GG, Qadan M, et al. Use of immunotherapy and surgery for stage Ⅳ melanoma[J]. Cancer, 2020, 126(11): 2614-2624.
|
22 |
Romano E, Michielin O. Successes and limitations of targeted cancer therapy in melanoma[J]. Prog Tumor Res, 2014, 41: 78-88.
|
23 |
Ko HS, Lee HJ, Kim SH, et al. Piceatannol suppresses breast cancer cell invasion through the inhibition of MMP-9: involvement of PI3K/AKT and NF-κB pathways[J]. J Agric Food Chem, 2012, 60(16): 4083-4089.
|
24 |
Winer A, Adams S, Mignatti P. Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes[J]. Mol Cancer Thera, 2018, 17(6): 1147-1155.
|
25 |
Melincovici CS, Boşca AB, Şuşman S, et al. Vascular endothelial growth factor (VEGF)-key factor in normal and pathological angiogenesis[J]. Rom J Morphol Embryol, 2018, 59(2): 455-467.
|
26 |
Mócsai A, Ruland J, Tybulewicz VLJ. The Syk tyrosine kinase: a crucial player in diverse biological functions[J]. Nat Rev Immunol, 2010, 10(6): 387-402.
|